A study comparing different zinc doses for the treatment of Wilson disease in healthy participants.

2 1 1

What is this study about?

This study focuses on Wilson Disease, a rare condition where too much copper builds up in the body. The purpose of the study is to investigate how different doses of zinc affect the way the body absorbs copper through the intestines. Participants may receive Galzin, a medication used to manage copper levels, or a different dose known as ET-700. Some may also receive a placebo.

To understand how the medications work, a substance called copper (64cu) chloride is used during the study. This is followed by a PET/CT, which is a specialized type of imaging scan that uses a radioactive tracer to create detailed pictures of the body’s internal organs. By using this scan, researchers can measure the amount of copper that reaches the liver to see how much absorption has changed due to the different treatments.

Who Can Join the Study?

You must be older than 18 years of age.
Your BMI (Body Mass Index, which is a measure used to determine if a person has a healthy weight for their height) must be lower than 30.
Women who are able to become pregnant must agree to use reliable contraception (methods used to prevent pregnancy, such as an intrauterine device (IUD) or hormonal contraception like pills, implants, patches, or rings) from the start of the study until 14 days after the final scan, unless they choose to avoid sexual contact for religious or personal reasons.
On the day you receive the tracer (a small amount of a substance used for medical imaging), women who can become pregnant must have a negative urine pregnancy test.
You must provide signed informed consent (a written document showing you understand the study and agree to participate) before any study tests begin.
You must be able to read and understand Danish well enough to follow the study steps and understand the consent forms.
You must be a healthy volunteer, meaning you do not have any existing medical conditions being studied.

Who Cannot Join the Study?

You have had an X-ray examination (a type of medical imaging that uses radiation) within the last 12 months.
You have a known hypersensitivity (an allergic reaction) to copper, the tracer substance known as 64CuCl2, or any ingredients used to make the medications Galzin or ET-700.
A doctor decides you are not suitable because your blood tests (medical tests used to check your health by analyzing blood samples) show abnormal results.
You have any contraindications (specific medical reasons or conditions that make a particular treatment or medication unsafe for you) for taking Galzin.
You suffer from claustrophobia (an extreme fear of being in small or enclosed spaces).
You are pregnant, breastfeeding, or are planning to become pregnant before the study ends.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Region Midtjylland	Aarhus	Denmark

Trial status

Country	Status	Recruitment Start
Denmark	Recruiting	01.03.2026

Trial locations

Investigated drugs:

Zinc (administered as Galzin) is a mineral supplement used in this study to compare how well it helps manage copper levels in the body.

Zinc (administered as ET-700) is a mineral supplement being tested to see how effectively it can be used to control copper absorption.

Copper is a substance used in this study to help researchers track and measure how much copper is being absorbed through the intestines and moving into the liver using special imaging scans.

Wilson’s Disease – This is a rare genetic condition that prevents the body from properly breaking down and getting rid of copper. As a result, copper builds up in various organs, most notably in the liver and the brain. The condition progresses as the excess metal accumulates over time. This buildup can lead to damage in the liver and neurological issues. The rate of accumulation depends on the body’s ability to process the mineral.

Trial ID:

2025-523372-24-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A study comparing different zinc doses for the treatment of Wilson disease in healthy participants.

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?